2026-2034年全球細胞和基因治療臨床試驗市場規模、佔有率、趨勢和成長分析報告

細胞和基因療法臨床試驗的市場規模預計將從 2025 年的 128.1 億美元成長到 2034 年的 461.7 億美元，2026 年至 2034 年的複合年成長率為 15.31%。

細胞和基因療法的臨床試驗領域正經歷爆炸性成長，這反映了科學突破、監管政策變化以及對CAR-T療法、基因編輯和病毒載體技術投資的增加。目前，腫瘤學、罕見遺傳疾病和再生醫學領域的試驗正在進行，試驗採用病毒和非病毒遞送方式來引入、修飾或替換遺傳物質。這一成長得益於孤兒藥激勵政策的優惠以及生物技術公司與大型製藥公司之間日益密切的合作。

關鍵促進因素包括載體設計和CRISPR/核苷酸編輯平台的技術進步、病毒載體和細胞處理生產能力的提升，以及在多種骨髓惡性腫瘤中徵兆出的顯著臨床療效。法規結構提供的快速核准管道和仿單標示外用藥方案正在加速臨床試驗的啟動。此外，臨床試驗網路的完善和專業製造地的建設正在縮短患者用藥時間，並支持多中心合作研究。

未來前景廣闊但也錯綜複雜。拓展至固體癌、提升安全性以及建立可擴展的生產系統仍然是至關重要的挑戰。新一代遞送系統、現成的異體細胞療法以及體內基因編輯技術可望拓展適應症並降低成本。長期安全性監測和克服生產瓶頸預計將決定其商業性可行性。如果技術和物流方面的挑戰得以解決，細胞和基因療法有望從一種小眾、高成本的治療方法方法轉變為更廣泛適用的根治性選擇。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球細胞與基因治療臨床試驗市場：依階段分類

• 市場分析、洞察與預測
• 第一階段
• 第二階段
• 第三階段
• 第四階段

第5章：全球細胞與基因治療臨床試驗市場：依適應症分類

• 市場分析、洞察與預測
• 腫瘤學
• 心臟病學
• 中樞神經系統
• 肌肉骨骼系統
• 感染疾病
• 皮膚科
• 內分泌、代謝和遺傳性疾病
• 免疫學與炎症
• 眼科
• 血液學
• 胃腸病學
• 其他

第6章 全球細胞與基因治療臨床試驗市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和分銷通路合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Iqvia
  • ICON Plc
  • Laboratory Corporation Of America Holdings
  • Charles River Laboratories International Inc
  • Parexel International Corp
  • Syneos Health
  • Medpace Holdings Inc
  • PPD Inc
  • Novotech
  • Veristat LLC

The Cell And Gene Therapy Clinical Trials Market size is expected to reach USD 46.17 Billion in 2034 from USD 12.81 Billion (2025) growing at a CAGR of 15.31% during 2026-2034.

The cell and gene therapy clinical trials landscape has grown explosively, reflecting scientific breakthroughs, regulatory pathways, and rising investment in CAR-T, gene-editing, and viral-vector technologies. Trials span oncology, rare genetic disorders, and regenerative medicine, leveraging viral and non-viral delivery methods to introduce, modify, or replace genetic material. Growth has been bolstered by favorable orphan-drug incentives and increasing partnerships between biotech firms and large pharma sponsors.

Key drivers include technological advances in vector design, CRISPR and base-editing platforms, improved manufacturing capabilities for viral vectors and cell processing, and strong clinical efficacy signals in several hematologic malignancies. Regulatory frameworks that offer accelerated pathways and compassionate-use programs have encouraged trial initiation. Additionally, improved trial networks and specialized manufacturing hubs shorten time-to-patient and support multi-center studies.

Future prospects are substantial but complex: expansion into solid tumors, broader safety profiling, and scalable manufacturing remain critical challenges. Next-generation delivery systems, off-the-shelf allogeneic cell therapies, and in vivo gene-editing promise to expand indications and lower costs. Long-term safety monitoring and addressing manufacturing bottlenecks will determine commercial viability. If technical and logistical hurdles are solved, cell and gene therapies could transition from niche, high-cost treatments to more widely available curative options.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Indication

• Oncology
• Cardiology
• CNS
• Musculoskeletal
• Infectious Diseases
• Dermatology
• Endocrine, Metabolic, Genetic
• Immunology & Inflammation
• Ophthalmology
• Hematology
• Gastroenterology
• Others

COMPANIES PROFILED

• Iqvia, ICON Plc, Laboratory Corporation of America Holdings, Charles River Laboratories International Inc, Parexel International Corp, Syneos Health, Medpace Holdings Inc, PPD Inc, Novotech, Veristat LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET: BY PHASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Phase
• 4.2. Phase I Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Phase II Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Phase III Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Phase IV Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Musculoskeletal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Endocrine, Metabolic, Genetic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Immunology & Inflammation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. Gastroenterology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.13. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Phase
  • 6.2.2 By Indication
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Phase
  • 6.3.2 By Indication
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Phase
  • 6.4.2 By Indication
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Phase
  • 6.5.2 By Indication
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Phase
  • 6.6.2 By Indication
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Iqvia
  • 8.2.2 ICON Plc
  • 8.2.3 Laboratory Corporation Of America Holdings
  • 8.2.4 Charles River Laboratories International Inc
  • 8.2.5 Parexel International Corp
  • 8.2.6 Syneos Health
  • 8.2.7 Medpace Holdings Inc
  • 8.2.8 PPD Inc
  • 8.2.9 Novotech
  • 8.2.10 Veristat LLC